What is HC Wainwright's Estimate for Zymeworks Q1 Earnings?

Zymeworks Inc. (NYSE:ZYME - Free Report) - HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Zymeworks in a report issued on Monday, March 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.43) for the quarter, up from their previous forecast of ($0.46). HC Wainwright has a "Neutral" rating and a $13.00 price objective on the stock. The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Zymeworks' Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.95) EPS.

Other research analysts also recently issued reports about the company. Citigroup raised their price objective on Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a report on Friday, March 7th. JPMorgan Chase & Co. upgraded Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price target on the stock in a report on Monday, December 16th. Lifesci Capital initiated coverage on Zymeworks in a report on Tuesday. They issued an "outperform" rating and a $30.00 price target on the stock. Finally, Wells Fargo & Company lifted their price target on Zymeworks from $12.00 to $14.00 and gave the company an "equal weight" rating in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Zymeworks currently has a consensus rating of "Moderate Buy" and an average target price of $21.00.

Remove Ads

Zymeworks Stock Up 5.4 %

ZYME opened at $11.70 on Wednesday. The stock's fifty day moving average is $14.01 and its two-hundred day moving average is $13.66. The company has a market capitalization of $814.05 million, a P/E ratio of -7.80 and a beta of 1.13. Zymeworks has a 52 week low of $7.97 and a 52 week high of $17.70.

Institutional Trading of Zymeworks

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Polar Asset Management Partners Inc. acquired a new stake in Zymeworks during the 4th quarter worth about $527,000. Voloridge Investment Management LLC acquired a new stake in Zymeworks during the 4th quarter worth about $640,000. Point72 Asset Management L.P. lifted its position in Zymeworks by 565.8% during the 4th quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company's stock worth $4,833,000 after acquiring an additional 280,544 shares during the period. Nuveen Asset Management LLC lifted its position in Zymeworks by 0.4% during the 4th quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company's stock worth $3,031,000 after acquiring an additional 886 shares during the period. Finally, Deutsche Bank AG raised its stake in shares of Zymeworks by 1.2% during the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock valued at $22,645,000 after buying an additional 17,849 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company's stock.

Insider Transactions at Zymeworks

In other Zymeworks news, CEO Kenneth Galbraith sold 57,291 shares of Zymeworks stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $14.92, for a total transaction of $854,781.72. Following the completion of the sale, the chief executive officer now owns 47,543 shares of the company's stock, valued at approximately $709,341.56. The trade was a 54.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Ecor1 Capital, Llc purchased 204,098 shares of the stock in a transaction on Friday, January 10th. The shares were purchased at an average cost of $13.13 per share, with a total value of $2,679,806.74. Following the transaction, the director now owns 15,411,078 shares in the company, valued at $202,347,454.14. This trade represents a 1.34 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 603,539 shares of company stock valued at $8,384,708 and sold 89,601 shares valued at $1,336,847. Insiders own 1.92% of the company's stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.